Deepika Cattry
Memorial Sloan Kettering Cancer Center · 9 works · 4,729 citations · h-index 6
Top works
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
- The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients
- Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
- nivolumab In Patients With Relapsed Or Refractory Lymphoid Malignancies And Classical Hodgkin Lymphoma: Updated Results Of A Phase 1 Study (ca209-039) : 010
- A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.
- Sleep Patterns in Elementary School Children (Grades 2-5) and Adolescents (Grade 10)